1-20 of 42
Jake Shortt
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study

Clinical Trials & Observations
David T. Yeung, Naranie Shanmuganathan, John Reynolds, Susan Branford, Mannu Walia, Agnes S. M. Yong, Jake Shortt, Lynette Chee, Nicholas Viiala, Ilona Cunningham, David M. Ross, Alwyn D’Souza, Matthew Wright, Rosemary Harrup, Cecily Forsyth, Robin Filshie, Steven Lane, Peter Browett, Carolyn Grove, Andrew P. Grigg, Timothy P. Hughes
Journal: Blood
Blood (2024) 144 (19): 1993–2001.
https://doi.org/10.1182/blood.2024024657
Published: 2024
Includes: Supplemental data
Journal Articles

Patient-Reported Outcomes (PRO) of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naïve, Transfusion-Dependent (TD), Lower-Risk Myelodysplastic Syndromes (LR-MDS): Results from the Phase 3 COMMANDS Study

Esther Natalie Oliva, Uwe Platzbecker, Matteo Giovanni Della Porta, Guillermo Garcia-Manero, Valeria Santini, Pierre Fenaux, Jake Shortt, Rami S. Komrokji, Christopher Pelligra, Shien Guo, Jennifer Lord-Bessen, Hong Xiao, Aylin Yucel, Dimana Miteva, Shelonitda Rose, Sandra Kreitz, Mikkael A. Sekeres, Amer M. Zeidan
Journal: Blood
Blood (2023) 142 (Supplement 1): 4596.
https://doi.org/10.1182/blood-2023-174660
Published: 2023
Journal Articles

The ELEMENT-MDS Trial: A Phase 3 Randomized Study Evaluating Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Non-Transfusion-Dependent, Lower-Risk Myelodysplastic Syndromes

Amer M. Zeidan, Rami S. Komrokji, Rena Buckstein, Valeria Santini, Shelonitda Rose, Priya Malini, Glen Lew, Dimple Aggarwal, Karen L. Keeperman, Huijing Jiang, Ana Carolina Giuseppi, Jennie Zhang, Thomas Cluzeau, Jake Shortt, Uwe Platzbecker
Journal: Blood
Blood (2023) 142 (Supplement 1): 6503.
https://doi.org/10.1182/blood-2023-178635
Published: 2023
Journal Articles

Phase 1/2a Trial of Bomedemstat with or without All- Trans Retinoic Acid (ATRA) in Advanced Myeloid Malignancies

David M. Ross, William S. Stevenson, Jake Shortt, Julian Cooney, Ian Lewis, Hugh Young Rienhoff Jr.
Journal: Blood
Blood (2023) 142 (Supplement 1): 6494.
https://doi.org/10.1182/blood-2023-180924
Published: 2023
Journal Articles

The Nature of High-Risk Defining Events in Follicular Lymphoma Determines Overall Survival

Joshua W.D. Tobin, Rakin Chowdhury, Ross Salvaris, Alison Griffin, Venkata Chikatamarla, Amanda Goh, Tsz Hung Tong, Callum Birks, Sanjiv Jain, Elizabeth Goodall, Shreerang Sirdesai, Thomas Trevis, Steinepreis Elizabeth, Yiyang Chen, Harrison Black, Glenn Broadby, Li Li, Naadir Gutta, Kirk Lachlan Morris, Tara Cochrane, Judith Trotman, Dipti Talaulikar, Jake Shortt, Georgina Hodges, Chan Y. Cheah, Allison A Barraclough, Kate Manos, Anna M. Johnston, Jane Royle, Patrizia Mondello, Stephen M Ansell, Greg Hapgood
Journal: Blood
Blood (2023) 142 (Supplement 1): 1671.
https://doi.org/10.1182/blood-2023-185879
Published: 2023
Journal Articles

Bomedemstat (IMG-7289), an LSD1 Inhibitor, Manages the Signs and Symptoms of Essential Thrombocythemia (ET) While Reducing the Burden of Cells Homozygous for Driver Mutations

Joachim R. Goethert, Harinder Gill, Francesca Palandri, David M. Ross, Tara Cochrane, Stephen R. Larsen, Anna B. Halpern, Jake Shortt, James M. Rossetti, James Liang, Monia Marchetti, Andrew J. Wilson, Andrew Innes, Merit Hanna, William S. Stevenson, Alessandro M. Vannucchi, Maria Kleppe, Georges Natsoulis, Claire N Harrison, Hugh Young Rienhoff Jr.
Journal: Blood
Blood (2023) 142 (Supplement 1): 747.
https://doi.org/10.1182/blood-2023-179329
Published: 2023
Journal Articles

Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS): Full Analysis of the COMMANDS Trial

Guillermo Garcia-Manero, Uwe Platzbecker, Valeria Santini, Amer M. Zeidan, Pierre Fenaux, Rami S. Komrokji, Jake Shortt, David Valcarcel, Anna Jonasova, Sophie Dimicoli-Salazar, Ing Soo Tiong, Chien-Chin Lin, Jiahui Li, Jennie Zhang, Ana Carolina Giuseppi, Sandra Kreitz, Veronika Pozharskaya, Karen L. Keeperman, Shelonitda Rose, Thomas Prebet, Andrius Degulys, Stefania Paolini, Thomas Cluzeau, Matteo Giovanni Della Porta
Journal: Blood
Blood (2023) 142 (Supplement 1): 193.
https://doi.org/10.1182/blood-2023-178596
Published: 2023
Journal Articles

Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study

David T Yeung, Naranie Shanmuganathan, John Reynolds, Susan Branford, Mannu Walia, Agnes S. M. Yong, Jake Shortt, Kate Burbury, Lynette C.Y. Chee, Nick Viiala, Ilona Cunningham, David M. Ross, Alwyn Bernard D'Souza, Matthew P.F. Wright, Rosemary Anne Harrup, Cecily Forsyth, Robin Filshie, Peter J. Browett, Steven W. Lane, Carolyn Grove, Andrew P Grigg, Timothy P Hughes, on Behalf Of The ALLG
Journal: Blood
Blood (2023) 142 (Supplement 1): 865.
https://doi.org/10.1182/blood-2023-172583
Published: 2023
Journal Articles

Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CML

David T Yeung, Naranie Shanmuganathan, John Reynolds, Susan Branford, Mannu Walia, Agnes S.M. Yong, Jake Shortt, Kate Burbury, Nicholas Viiala, Ilona Cunningham, David M. Ross, Rosemary Harrup, Matthew Wright, Cecily Forsyth, Alwyn Bernard D'Souza, Robin J Filshie, Peter J. Browett, Steven W Lane, Carolyn Grove, Andrew Grigg, Timothy Hughes
Journal: Blood
Blood (2022) 140 (Supplement 1): 192–194.
https://doi.org/10.1182/blood-2022-157244
Published: 2022
Journal Articles

A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses

Kristen M. Pettit, Harinder Gill, Abdulraheem Yacoub, Terrence Bradley, Aaron T. Gerds, Maciej Tatarczuch, Jake Shortt, Natasha Joan Curtin, James M. Rossetti, Kate Burbury, Adam J Mead, Joachim R Göthert, Steffen Koschmieder, Matt Reyer, Benjamin Siranosian, Georges Natsoulis, William S Stevenson, Joanne Ewing, Joseph M. Chacko, Elisa Rumi, Anna B. Halpern, Francesca Palandri, Nicola Vianelli, Francesco Passamonti, Ruben Mesa, Monia Marchetti, Claire Harrison, Alessandro M. Vannucchi, Justin Watts, David M Ross, Moshe Talpaz, Hugh Young Rienhoff, Jr.
Journal: Blood
Blood (2022) 140 (Supplement 1): 9717–9720.
https://doi.org/10.1182/blood-2022-167122
Published: 2022
Journal Articles

Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)

Jake Shortt, Pau Montesinos, Shuh Ying Tan, Teng Fong Ng, Chun Yew Fong, Paul Cannell, Rajeev Rajagopal, Sophia Leitch, Peter T. Tan, Sundra Ramanathan, Robin Gasiorowski, Douglas Stuart Lenton, Tse-Chieh Teh, José Antonio Pérez-Simón, Carolyn Grove, Xiaojun Huang, Courtney D. DiNardo, Katherine Naidu, Joseph Pariseau, Si Cheng, Yu Liu, Melannie Co, Wai Y. Chan, Haiyi Guo, Andrew H. Wei
Journal: Blood
Blood (2022) 140 (Supplement 1): 3329–3332.
https://doi.org/10.1182/blood-2022-166937
Published: 2022
Journal Articles

A Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects with Relapsed/Refractory Peripheral T-Cell Lymphoma

Jake Shortt, Brian Poligone, Vincent Ribrag, Pier Luigi Zinzani, Dima El-Sharkawi, Jan Walewski, Anca Prica, Laksmi Wilson, Sonia Souza, Harold N. Keer, Jason A. Taylor, Enrica Marchi
Journal: Blood
Blood (2022) 140 (Supplement 1): 12033–12034.
https://doi.org/10.1182/blood-2022-158650
Published: 2022
Journal Articles

A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)

Harinder Gill, Francesca Palandri, David M Ross, Tara Cochrane, Courtney Tate, Steven W Lane, Stephen R Larsen, Aaron T. Gerds, Anna B. Halpern, Jake Shortt, James M. Rossetti, Kristen M. Pettit, James Liang, Adam J Mead, Monia Marchetti, Alessandro M. Vannucchi, Andrew J Wilson, Joachim R Göthert, Merit Hanna, Francesco Passamonti, William S Stevenson, Claire Harrison, Moshe Talpaz, Nicola Vianelli, Hugh Young Rienhoff, Jr.
Journal: Blood
Blood (2022) 140 (Supplement 1): 1784–1787.
https://doi.org/10.1182/blood-2022-159047
Published: 2022
Journal Articles

A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Essential Thrombocythemia (ET)

Francesca Palandri, Nicola Vianelli, David M Ross, Tara Cochrane, Steven W Lane, Stephen R Larsen, Aaron T. Gerds, Anna B. Halpern, Jake Shortt, James M. Rossetti, Kristen M. Pettit, Amber Jones, Jennifer Peppe, Georges Natsoulis, Willis Navarro, Wan-Jen Hong, William S. Stevenson, Claire N. Harrison, Moshe Talpaz, Hugh Young Rienhoff, Jr.
Journal: Blood
Blood (2021) 138 (Supplement 1): 386.
https://doi.org/10.1182/blood-2021-148210
Published: 2021
Journal Articles

Real-World Outcomes of Patients with Primary CNS Lymphoma (PCNSL): A Report from the Australasian Lymphoma Alliance (ALA)

Maciej Tatarczuch, Katharine Louise Lewis, Ashray Gunjur, Briony Shaw, Michelle Poon, Erin Paul, Matthew Ku, Mark Wong, Ashley Beekman, Michael Krigstein, Pietro R Di Ciaccio, Joel Wight, Caitlin Coombes, Michael Gilbertson, Amanda Tey, Jake Shortt, Chandramouli Nagarajan, Maya Latimer, Dipti Talaulikar, Nada Hamad, Sumita Ratnasingam, Tara Cochrane, Eliza Hawkes, Chan Yoon Cheah, Stephen Opat, Gareth P Gregory
Journal: Blood
Blood (2021) 138 (Supplement 1): 2532.
https://doi.org/10.1182/blood-2021-145959
Published: 2021
Journal Articles

A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis

Harinder Gill, Abdulraheem Yacoub, Kristen M. Pettit, Terrence Bradley, Aaron T. Gerds, Maciej Tatarczuch, Jake Shortt, Natasha Joan Curtin, James M. Rossetti, Kate Burbury, Adam J. Mead, Joachim R. Göthert, Steffen Koschmieder, Amber Jones, Jennifer Peppe, Georges Natsoulis, Wan-Jen Hong, William S. Stevenson, Joanne Ewing, Claire N. Harrison, Alessandro Vannucchi, Justin Watts, David M Ross, Moshe Talpaz, Hugh Young Rienhoff, Jr.
Journal: Blood
Blood (2021) 138 (Supplement 1): 139.
https://doi.org/10.1182/blood-2021-148682
Published: 2021
Journal Articles

Large Population Dataset Linkage to Understand Evolving Practice in Red Cell and Platelet Transfusion and Clinical Outcomes in Patients with Myelodysplastic Syndromes (MDS): A 15-Year Study

Allison Mo, Jake Shortt, Erica M. Wood, Zoe K McQuilten
Journal: Blood
Blood (2021) 138 (Supplement 1): 3255.
https://doi.org/10.1182/blood-2021-147132
Published: 2021
Journal Articles

Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study

Eliza A Hawkes, Kate Manos, Geoff Chong, Jodie Palmer, Michael MacManus, Colm Keane, MD, Andrew Scott, Jake Shortt, MBBS FRACP FRCPA PhD, David Ritchie, MD PhD, Leonid Churilov, Laura Johnston, Tom Witkowski, Allison Barraclough, Sze-Ting Lee, Wendi Lin, Rachel Koldej, Richard Khor
Journal: Blood
Blood (2019) 134 (Supplement_1): 5328.
https://doi.org/10.1182/blood-2019-122635
Published: 2019
Journal Articles

A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis

Kristen Pettit, MD, Aaron T. Gerds, MD MS, Abdulraheem Yacoub, MD, Justin M. Watts, MD, Maciej Tartaczuch, MD, Terrence J Bradley, MD, Jake Shortt, MBBS FRACP FRCPA PhD, William S. Stevenson, MBBS,PhD, Natasha Joan Curtin, MDFRACP,FRCPA, James M. Rossetti, DO, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Georges Natsoulis, PhD, Amber Jones, MA, Moshe Talpaz, MD, Jennifer Peppe, BS, David M Ross, MD PhD, Hugh Young Rienhoff, Jr., MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 556.
https://doi.org/10.1182/blood-2019-123244
Published: 2019
Journal Articles

Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study

David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Andrew Grigg, Naranie Shanmuganathan, MBBS FRACP FRCPA, Ann Christine Solterbeck, BSc(Hons) MSc PhDAstat, Deborah L. White, PhD FFSc (RCPA), Susan Branford, PhD FFSc (RCPA), Nicholas Viiala, MBBS FRACP FRCPA, Philip Arthur Rowlings, FRACP,FRCPA,MBBS,MS, Anthony K Mills, FRACP, FRCPA, MBBS, Jake Shortt, MBBS FRACP FRCPA PhD, Campbell Tiley, MBBS, FRACP, David M Ross, MD PhD, David Kipp, MBBS,FRCPA,FRACP, Rosemary Anne Harrup, MBBS, FRACP, FRCPA, Ilona Cunningham, MBBS FRACP FRCPA, John Kwan, MBBS,FRACP,FRCPA, Richard Eek, MBChB MMED, FCP, FRACP., Howard Mutsando, MBChB FRACP FRCPA, Ken-Soon Tan, MMed FRACP MRCP(UK) MA MBBChir BA(Hons), Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Matthew P.F. Wright, MBBS, FRCPA, FRACP, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, On Behalf of the ALLG
Journal: Blood
Blood (2019) 134 (Supplement_1): 4150.
https://doi.org/10.1182/blood-2019-127619
Published: 2019